ArticleBMJ public health2026
Prevalence of zero-dose vaccination and its associated factors in urban areas of Somali region, Ethiopia: a mixed-methods approach.
Article in BMJ public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Despite global progress in immunisation, vaccine coverage remains uneven in many low- and middle-income countries. Urbanisation has widened disparities, particularly among children in informal settlements. Ethiopia has a high zero-dose burden, with the Somali region identified as a hotspot. However, urban areas in this region remain understudied. This study assesses the prevalence of zero-dose children and associated factors in urban areas of the Somali region to inform targeted interventions. Methods: Using a mixed-methods approach, data were collected from 842 households in three urban towns through community surveys and six key informant interviews. The primary outcome was the proportion of zero-dose children, defined as those who had not received the first dose of the DTP-containing vaccine (Penta-1) during their first year of life, based on vaccination card records or caregiver recall. This included children who had never received any vaccine or had received some vaccines but not Penta-1. Quantitative data were analysed using logistic regression, while qualitative findings were examined thematically using the GAVI IRMMA framework. Strict quality control measures ensured the reliability of results. Results: Of 842 targeted households, 827 participated (98.2% response). Findings reveal that 30% of children surveyed were identified as zero-dose for vaccination. Children were significantly more likely to be zero-dose if their mothers had no antenatal care (adjusted OR, AOR ~5.0), required permission for vaccination (AOR ~3.4), delivered at home (AOR ~3.1), or did not receive the second dose of tetanus toxoid (AOR ~2.7). In contrast, higher perceived household wealth and at least one postnatal care visit reduced the likelihood of zero-dose by about 45% and 55%, respectively. Zero-dose children were concentrated in urban peripheries and informal settlements with limited healthcare access, poor identification strategies and reliance on facility-based vaccination services. Conclusions: The study highlights a higher prevalence of zero-dose children in urban areas, underscoring the urgent need for improved identification and mapping in underserved communities. Strengthening advocacy, diversifying immunisation approaches and addressing systemic barriers are essential to improving vaccine access and reducing the zero-dose burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.